

INVITATION TO INVESTOR CALL RELATED TO THE SESAR STUDY RESULTS

Sedana Medical hereby invites to an investor call related to the results of the investigator initiated SESAR study today 19 March at 15:00 CET

Yesterday (18 March) the investigator initiated study "Sevoflurane for sedation in Acute Respiratory Distress Syndrome (ARDS)", the SESAR study, was published in The Journal of American Medicine (JAMA). Related to this, Sedena Medical invites investors and analysts to a digital presentation of the company's assessment of the study results, and an opportunity to ask questions to the company's CEO Johannes Doll and CMO Peter Sackey.

Date: Wednesday 19 March, 2025

Time: 15:00 CET

Link to presentation: https://www.finwire.tv/webcast/sedana-medical/investor-call/ If you wish to participate via teleconference: +46 8 5016 3827. Meeting ID: 825 3412 1573.

Welcome!

For additional information, please contact:


Johannes Doll, CEO, +46 (0)76 303 66 66 Johan Spetz, CFO, +46 (0)730 36 37 89 ir@sedanamedical.com

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.





A ₁	ta	ch	m	er	ıts
----------------	----	----	---	----	-----

Invitation to investor call related to the SESAR study results